Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MK-1708 in Healthy Elderly Participants
NCT06647628Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mk-1708 in Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of participants with ≥1 adverse event, Number of participants discontinuing study therapy due to AE and 10 more. Started Nov 2024; status: completed.
02
Drugs
mk-1708
03
Conditions
Alzheimer's disease (AD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06647628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647628.